Table of Content

1. Introduction 16
1.1 Scope of the Study. 16

2. Pharmaceutical Market – Key Takeaways 17

3. Research Methodology 21
3.1 Coverage. 22
3.2 Secondary Research. 23
3.3 Primary Research. 24

4. Pharmaceutical Market – Market Landscape 25
4.1 Overview. 25
4.2 PESTLE Analysis. 25
4.2.1 Political Factors. 25
4.2.2 Economic Factors. 25
4.2.3 Social Factors. 26
4.2.4 Technological Factors. 26
4.2.5 Legal Factors. 27
4.2.6 Environmental Factors. 27
4.3 Expert’s Opinion. 28
4.4 Macro-Economic Framework of the U.S. 28
4.5 Import and Export Activities in the U.S. and Italy. 31
4.5.1 Import – Export Analysis. 31
4.5.2 US. 37
4.5.3 Italy. 50
4.6 Magazines, Publications, Universities, and Online Portals. 60
4.7 Events List 65
4.8 Trade Shows List 67
4.9 Useful Contacts -Events and Trade Shows, Associations, and Magazines. 68
4.9.1 Associations - MAIN PHARMACEUTICAL, VACCINE AND CONSUMER PRODUCT TRADE ASSOCIATIONS. 74
4.9.2 Magazines – Trade Magazines, Blogs, Journals, and Publications. 81
4.10 Information Regarding CDMOs. 84
4.10.1 Surplus/Deficit information. 84
4.10.2 Trade Balance. 84
4.10.3 Production and investment Done in the recent Past 85
4.10.4 Initiatives Taken by Pharmaceutical Countries. 86
4.11 Supply Chain Distribution Channel 87
4.12 Suggestions and Opportunities For Italian Companies. 98
4.13 Industry Performance. 99
4.14 Industry Outlook. 100
4.14.1 Market Size and Growth. 100
4.14.2 Research and Development (R&D) 100
4.14.3 Market Dynamics. 100
4.14.4 Regulatory Landscape. 101
4.14.5 Market Access and Pricing. 101
4.14.6 COVID-19 Impact 101
4.14.7 Generics and Biosimilars. 101
4.14.8 Digital Health Integration. 101
4.14.9 Supply Chain Resilience. 102
4.14.10 Workforce and Employment 102
4.14.11 Downward Pressure on Pricing. 102
4.14.12 From Treatment to Prevention and Beyond. 103
4.15 Key External Drivers. 103
4.15.1 Increasing Geriatric Population. 103
4.15.2 Advantages Offered by Continuous Manufacturing Process. 104
4.16 Demand Determinants in Future. 104
4.16.1 Growing Interest of Pharmaceutical Companies to Promote Product Sales through Contract Sales Organizations. 104
4.16.2 Rising Number of Healthcare Start-ups. 105
4.17 Industry Trends in the US Market 106
4.17.1 Increasing Adoption of Continuous Manufacturing in Pharmaceuticals. 106
4.17.2 Growing Adoption of AI-based Tools for Drug Discovery. 106
4.17.3 Growing Adoption of Self-Injecting Parenteral Devices. 106

5. Pharmaceutical Market – Key Market Dynamics 110
5.1 Market Drivers. 110
5.1.1 Rising Workplace-Associated Disorders. 110
5.1.2 Rise in Pharmaceutical Production Capacity. 111
5.1.3 Increased Approvals of Generic Drugs. 112
5.1.4 Escalating R&D Investments in Pharmaceutical Industry. 112
5.2 Market Restraints. 113
5.2.1 High Cost of Drug Development and Marketing Approval 113
5.3 Market Opportunities. 113
5.3.1 Rising Incidences of Chronic Diseases and Infectious Diseases. 113
5.3.2 Emerging Markets for Outsourcing Production Activities. 114
5.4 Future Trends. 115
5.4.1 Increasing Adoption of AI-based Tools for Drug Discovery. 115
5.5 Impact Analysis. 116

6. Pharmaceutical Market – US Analysis 117
6.1 US Pharmaceutical Market Revenue Forecast and Analysis. 117
6.1.1 US: Pharmaceutical Market, by Product, 2019–2030 (US$ Billion) 118
6.1.1.1 US: Pharmaceuticals Market For Product, by Type, 2019–2030 (US$ Billion) 118
6.2 Production mapping. 119
6.2.1 Pharma companies in the US- 119
6.2.2 The impact of COVID-19 on R&D- 119
6.3 Pricing Analysis of Key Products. 119
6.4 Production and Sales Statistics of Pharmaceutical Market in US. 122
6.5 Value Chain Analysis and Vendor’s Ecosystem.. 124
6.6 Go-to-Market Strategies for Companies. 125
6.6.1 Johnson & Johnson. 125
6.6.2 Pfizer Inc. 126
6.6.3 Merck Co & Inc. 126
6.7 Regulatory Scenario in the United States Associated With Pharmaceutical Industry. 127
6.7.1 Agencies, Organizations, Institutes, Centers, and Offices Associated with Pharmaceutical Product Regulation. 128
6.7.2 Regulations to enter and operate within the USA Market 128
6.8 HTS Codes for Drugs in United States. 129
6.8.1 Custom Duties. 131
6.8.2 Link Between HTS Codes and Custom Duties. 131

7. US Branded Small Molecules Market 132
7.1 US: Branded Small Molecules Market Revenue and Forecast to 2030. 132
7.1.1 Overview. 132
7.1.2 US: Branded Small Molecules Market Positioning Analysis. 134
7.1.3 US Branded Small Molecules Market – Revenue and Forecast to 2030 (USD Billion) 135

8. US Generic Small Molecules Market 136
8.1 US: Generic Small Molecules Market Revenue and Forecast to 2030. 136
8.1.1 Overview. 136
8.1.2 US: Generic Small Molecules Market Positioning Analysis: 138
8.1.3 US Generic Small Molecules Market – Revenue and Forecast to 2030 (USD Billion) 139

9. US Biological and Biosimilar Products Market 140
9.1 US: Biological and Biosimilar Products Market Revenue and Forecast to 2030. 140
9.1.1 Overview. 140
9.1.2 US: Biological and Biosimilar Products Market Positioning Analysis: 142
9.1.3 US Biological and Biosimilar Products Market – Revenue and Forecast to 2030 (USD Billion) 143

10. US Vaccines Market 144
10.1 US: Vaccines Market Revenue and Forecast to 2030. 144
10.1.1 Overview. 144
10.1.2 US: Vaccines Market Positioning Analysis: 146
10.1.3 US Vaccines Market – Revenue and Forecast to 2030 (USD Billion) 147

11. Pharmaceutical Market – Industry Landscape 148
11.1 Overview. 148
11.2 Growth Strategies in the Pharmaceutical Market 148
11.3 Inorganic Growth Strategies. 149
11.3.1 Overview. 149
11.4 Organic Growth Strategies. 150
11.4.1 Overview. 150

12. Company Profiles 152
12.1 Moderna Inc. 152
12.1.1 Key Facts. 152
12.1.2 Business Description. 152
12.1.3 Products and Services. 153
12.1.4 Financial Overview. 154
12.1.5 SWOT Analysis. 156
12.1.6 Key Developments. 158
12.2 AbbVie Inc. 159
12.2.1 Key Facts. 159
12.2.2 Business Description. 159
12.2.3 Products and Services. 160
12.2.4 Financial Overview. 161
12.2.5 SWOT Analysis. 164
12.2.6 Key Developments. 168
12.3 Gilead Sciences Inc. 169
12.3.1 Key Facts. 169
12.3.2 Business Description. 169
12.3.3 Products and Services. 170
12.3.4 Financial Overview. 171
12.3.5 SWOT Analysis. 173
12.3.6 Key Developments. 177
12.4 Regeneron Pharmaceuticals Inc. 178
12.4.1 Key Facts. 178
12.4.2 Business Description. 178
12.4.3 Products and Services. 179
12.4.4 Financial Overview. 180
12.4.5 SWOT Analysis. 181
12.4.6 Key Developments. 185
12.5 Merck & Co Inc. 186
12.5.1 Key Facts. 186
12.5.2 Business Description. 186
12.5.3 Products and Services. 187
12.5.4 Financial Overview. 188
12.5.5 SWOT Analysis. 191
12.5.6 Key Developments. 195
12.6 Abbott Laboratories. 196
12.6.1 Key Facts. 196
12.6.2 Business Description. 196
12.6.3 Products and Services. 197
12.6.4 Financial Overview. 199
12.6.5 SWOT Analysis. 202
12.6.6 Key Developments. 206
12.7 Bristol-Myers Squibb Co. 207
12.7.1 Key Facts. 207
12.7.2 Business Description. 207
12.7.3 Products and Services. 208
12.7.4 Financial Overview. 209
12.7.5 SWOT Analysis. 211
12.7.6 Key Developments. 215
12.8 Vertex Pharmaceuticals Inc. 216
12.8.1 Key Facts. 216
12.8.2 Business Description. 216
12.8.3 Products and Services. 217
12.8.4 Financial Overview. 218
12.8.5 SWOT Analysis. 220
12.8.6 Key Developments. 222
12.9 Pfizer Inc. 223
12.9.1 Key Facts. 223
12.9.2 Business Description. 223
12.9.3 Products and Services. 224
12.9.4 Financial Overview. 225
12.9.5 SWOT Analysis. 227
12.9.6 Key Developments. 231
12.10 Eli Lilly and Co. 233
12.10.1 Key Facts. 233
12.10.2 Business Description. 233
12.10.3 Products and Services. 234
12.10.4 Financial Overview. 235
12.10.5 SWOT Analysis. 237
12.10.6 Key Developments. 241
12.11 Bayer AG. 242
12.11.1 Key Facts. 242
12.11.2 Business Description. 242
12.11.3 Products and Services. 243
12.11.4 Financial Overview. 245
12.11.5 SWOT Analysis. 248
12.11.6 Key Developments. 251
12.12 Johnson & Johnson. 252
12.12.1 Key Facts. 252
12.12.2 Business Description. 252
12.12.3 Products and Services. 253
12.12.4 Financial Overview. 256
12.12.5 SWOT Analysis. 258
12.12.6 Key Developments. 262
12.13 Amgen Inc. 264
12.13.1 Key Facts. 264
12.13.2 Business Description. 264
12.13.3 Products and Services. 265
12.13.4 Financial Overview. 266
12.13.5 SWOT Analysis. 268
12.13.6 Key Developments. 272
12.14 Takeda Pharmaceutical Co Ltd. 273
12.14.1 Key Facts. 273
12.14.2 Business Description. 273
12.14.3 Products and Services. 274
12.14.4 Financial Overview. 275
12.14.5 SWOT Analysis. 278
12.14.6 Key Developments. 282
12.15 Zoetis Inc. 283
12.15.1 Key Facts. 283
12.15.2 Business Description. 283
12.15.3 Products and Services. 284
12.15.4 Financial Overview. 285
12.15.5 SWOT Analysis. 287
12.15.6 Key Developments. 290



List of Figures

LIST OF FIGURES

Figure 1. Pharmaceutical Market Overview.. 17
Figure 2. Small Molecules Segment Held Largest Share of Product Segment in Pharmaceutical Market 17
Figure 3. Pharmaceutical Market – Industry Landscape. 19
Figure 4. Experts’ Opinion. 28
Figure 5. List of supplying markets for pharmaceutical product imported by United States. 37
Figure 6. List of supplying markets for pharmaceutical product imported by United States in US$ Thousand. 38
Figure 7. List of importing markets for a product exported by United States. 40
Figure 8. List of importing markets for a product exported by United States. 41
Figure 9. List of importing markets for a product exported by United States. 42
Figure 10. List of supplying markets for a product imported by Italy. 50
Figure 11. List of supplying markets for a product imported by Italy. 50
Figure 12. List of importing markets for a product exported by Italy. 51
Figure 13. List of importing markets for a product exported by Italy. 52
Figure 14. List of importing markets for a product exported by Italy. 53
Figure 15. Key Trends Impact 108
Figure 16. Key Trends Impact 109
Figure 17. Pharmaceutical Market Impact Analysis of Driver and Restraints. 116
Figure 18. US Pharmaceutical Market – Revenue Forecast and Analysis – 2020–2030. 117
Figure 19. US Branded Small Molecules Market Revenue and Forecast to 2030 (USD Billion) 135
Figure 20. US Generic Small Molecules Market Revenue and Forecast to 2030 (USD Billion) 139
Figure 21. US Biological and Biosimilar Products Market Revenue and Forecast to 2030 (USD Billion) 143
Figure 22. US Biological and Biosimilar Products Market Revenue and Forecast to 2030 (USD Billion) 147
Figure 23. Growth Strategies in the Pharmaceutical Market 148

List of Tables

LIST OF TABLES

Table 1. US Export Trade to Italy- Product: HSC 30 Pharmaceutical products. 43
Table 2. US Export Trade to Italy- Product: HSC 30 Pharmaceutical products. 44
Table 3. US Import Trade from Italy- Product: HSC 30 Pharmaceutical products. 47
Table 4. US Import Trade from Italy- Product: HSC 30 Pharmaceutical products. 48
Table 5. Italy Import Trade from US- Product: HSC 30 Pharmaceutical products. 54
Table 6. Italy Import Trade from US- Product: HSC 30 Pharmaceutical products. 55
Table 7. Italy Export Trade from US- Product: HSC 30 Pharmaceutical products. 58
Table 8. Italy Export Trade to US- Product: HSC 30 Pharmaceutical products. 59
Table 9. List of Magazines, Publications, Universities, and Online Portals. 61
Table 10. List of Events. 65
Table 11. List of Trade Shows. 67
Table 12. Events and Trade Shows. 68
Table 13. Counts of total nonfatal occupational injuries, illnesses, and respiratory illnesses (private industry, 2018–2022) (Thousand) 110
Table 14. US Pharmaceutical Market, by Product – Revenue and Forecast to 2030 (US$ Billion) 118
Table 15. US Pharmaceuticals Market For Product, by Type – Revenue and Forecast to 2030 (US$ Billion) 118
Table 16. Top Drugs by Price Increase, January and July 2022. 120
Table 17. Top Drugs by Percentage Price Increase, January and July 2022. 121
Table 18. Global Demand of Pharmaceutical (US$ Billion) 123
Table 19. Global Production of Pharmaceutical (US$ Billion) 123
Table 20. Production Size in US (US$ Billion) 123
Table 21. Novel Drug Approvals for 2023. 133
Table 22. Recent Generic Small Molecules Approvals by US FDA. 137
Table 23. Recent Biological and Biosimilar Products Approvals by US FDA. 141
Table 24. Recent Vaccines Approvals by US FDA. 145
Table 25. Recent Inorganic Growth Strategies in the Pharmaceutical Market 149
Table 26. Recent Organic Growth Strategies in the Pharmaceutical Market 151